Raman to Study Radiation Damage in Cells, Tissues
News May 26, 2016
Dr Andrew Jirasek from the University of British Columbia – Okanagan with his Renishaw inVia Raman microscope
The Irving K Barber School of Arts and Sciences at the University of British Columbia, Canada, hosts a multidisciplinary group of physics, engineering and radiation oncology scientists. It is interested in detecting and understanding damage in cells and tissues due to ionizing radiation used in cancer treatments. Currently the dose a patient receives is prescribed based on population averages and does not take individual patient radio sensitivity into account. The ultimate aim of the group is to help personalize prescriptions based on an individual's response to radiation.
In some cases, it is possible to use Raman spectroscopic techniques to detect radiation damage in patients. The group is conducting research to find out if it is possible to make an early detection tool based on Raman spectroscopy, either prior to first treatment or within the first few fractions of treatment.
Associate Professor, Andrew Jirasek, is a physicist by training who has specialised in how to accurately measure radiation treatments for cancer patients. Together with his colleagues, Dr Jirasek was the first to apply Raman spectroscopy to look at the unique cellular changes that occur following radiation. He says. “This is a very powerful technique. We can record and analyse information about how the molecules and cellular constituents change throughout treatment.” Dosage can then be adjusted to be more precise and targeted. He continues, “Previously, the only outcome of treatment was disease status; for example, tumour size. Our hope is that Raman analysis will provide accurate treatment evaluation sooner. Like many other diseases, timing with cancer treatment is everything. The sooner successful therapy is implemented, the better for the patient.” After conducting cell and animal model experiments, the group is now at the point of testing the system on prostate cancer patients.
Describing the choice of the Renishaw inVia Raman microscope for this work, Dr Jirasek said, “We chose the inVia for multiple reasons. The system delivers excellent Raman sensitivity and throughput. It also offers us high potential for automation. Because the system is used by multiple groups and types of users, ease of use is important to maximise our ‘up time’. With several users not being experts in Raman, we have appreciated the excellent customer service support we have had from Renishaw.”
Dr Jirasek's work has been well reported and has recently appeared in several publications as well as presentations at conferences. Notable among these include “A Raman spectroscopic study of cell response to clinical doses of ionizing radiation”1 and “Raman spectroscopy identifies radiation response in human non-small cell lung cancer xenografts.”2 Full details of this research program and publications may be viewed at Dr Jirasek's homepage: http://medicalphysics.ok.ubc.ca/faculty/jirasek.html.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
The Friedrich Schiller University Jena Partners with ACD/Labs to Advance its Analytical Data Management StrategyNews
Implementation of ACD/Spectrus as an analytical data management system helps researchers and students streamline NMR and MS data processing, interpretation, collaboration, and training.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE